Evidence map›Paper›PMID 24959595›Full record

SynthesisBioMed research international2014

Heart failure in patients with chronic kidney disease: a systematic integrative review.

Liviu Segall, Ionut Nistor, Adrian Covic

Registry-linked trialOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05557929 (Cardiopulmonary Exercise Testing Parameters' Variability During Long and Short Interdialytic Intervals in Hemodialysis Patients.), which is not on this map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05557929 completednot on this mapstarted 2021, after this paper: background citation

Cardiopulmonary Exercise Testing Parameters' Variability During Long and Short Interdialytic Intervals in Hemodialysis Patients.

TypeobservationalSponsorAristotle University Of ThessalonikiRan2021 to 2023Enrolled28ConditionsChronic Kidney Disease Requiring Chronic Dialysis, Chronic Kidney Diseases
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Mitigating Bias in Opportunistic Screening for MACE with Causal Reasoning.IEEE transactions on artificial intelligence · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Global epidemiology of heart failure.Nature reviews. Cardiology · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Liviu SegallNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy "Gr. T. Popa", Strada. Universităţii No. 16, 700115 Iaşi, Romania.
Ionut NistorNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy "Gr. T. Popa", Strada. Universităţii No. 16, 700115 Iaşi, Romania.
Adrian CovicNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy "Gr. T. Popa", Strada. Universităţii No. 16, 700115 Iaşi, Romania.
Grigore T. Popa University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHeart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and is strongly associated with mortality in these patients. However, the treatment of HF in this population is largely unclear. STUDY

designWe conducted a systematic integrative review of the literature to assess the current evidence of HF treatment in CKD patients, searching electronic databases in April 2014. Synthesis used narrative methods. SETTING AND POPULATION: We focused on adults with a primary diagnosis of CKD and HF. SELECTION CRITERIA FOR STUDIES: We included studies of any design, quantitative or qualitative.

interventionsHF treatment was defined as any formal means taken to improve the symptoms of HF and/or the heart structure and function abnormalities. OUTCOMES: Measures of all kinds were considered of interest.

resultsOf 1,439 results returned by database searches, 79 articles met inclusion criteria. A further 23 relevant articles were identified by hand searching.

conclusionsControl of fluid overload, the use of beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and optimization of dialysis appear to be the most important methods to treat HF in CKD and ESRD patients. Aldosterone antagonists and digitalis glycosides may additionally be considered; however, their use is associated with significant risks. The role of anemia correction, control of CKD-mineral and bone disorder, and cardiac resynchronization therapy are also discussed.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsGlomerular Filtration RateHeart FailureHumansKidney Failure, ChronicRenal Insufficiency, ChronicRisk FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Identifiers

PMID24959595
PMCPMC4052068
OpenAlexW2170664634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.